EMEA-001886-PIP02-15-M01
Key facts
| Active substance |
Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689)
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0223/2017
|
| PIP number |
EMEA-001886-PIP02-15-M01
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of congenital Factor VII Deficiency
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
CSL Behring GmbH
Tel.: +49 6421393304 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|